-+ 0.00%
-+ 0.00%
-+ 0.00%
TheraCryf Files Ethics Application for First-Stage Study of Orexin-1 Addiction Program
Share
Listen to the news
04:15 AM EST, 11/18/2026 (MT Newswires) -- TheraCryf (TCF.L) submitted an ethics application in Australia for a first-in-human phase 1 clinical trial of its lead orexin-1 receptor antagonist, which is being developed to treat addiction. The application was filed with the Bellberry Human Research Ethics Committee through its Australian subsidiary, following completion of the required preclinical data package, according to a Wednesday release. Subject to ethics committee approval, the clinical-stage therapeutics company will file a clinical trial notification with Australia's Therapeutic Goods Administration. It continues to target the necessary approvals by the end of 2026.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending